OncoTAb
OncoTAb is a Charlotte, NC-based biotech founded in 2011 that develops a blood-based diagnostic test to aid breast cancer detection in women with dense breast tissue, a population where mammography sensitivity is reduced.
- Company typePrivate
- Founded2011
- HeadquartersCharlotte, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What OncoTAb does
OncoTAb is a Charlotte, North Carolina-based biotechnology company founded in 2011 that develops a blood-based diagnostic test intended to aid breast cancer detection, with specific positioning for women with dense breast tissue — a population in which standard mammography exhibits reduced sensitivity. The company's product addresses an underserved clinical niche where imaging-based screening is known to underperform, and its biomarker-based approach offers a complementary modality to mammography. The company is led by Founder Pinku Mukherjee in the President & Chief Science Officer role, alongside CEO Rahul Puri, operating with a lean team of 1-10 employees.
The underlying technology and clinical-validation status (e.g., biomarker identity, assay format, FDA pathway, peer-reviewed evidence) are not described in the available sources, and the company's website currently returns only a verification/loading page with no substantive disclosure. No customers, distribution channels, pricing model, or revenue mechanics are documented in the input data. The only external ecosystem engagement on record is participation in the MedTech Innovator program in May 2017.
Business model signals are absent from the input: pricing, reimbursement strategy, target buyer (clinicians, labs, payers, or direct-to-consumer), and go-to-market motion are all undisclosed. With a single non-equity ecosystem engagement on record and no subsequent priced funding rounds visible, the company appears to be in a very early-stage or capital-constrained posture. Investors should treat the public information set as thin and prioritize diligence on clinical validation status, regulatory pathway, IP position, and runway before underwriting.
OncoTAb firmographics
Firmographics- Name
- OncoTAb
- Website
- https://oncotab.com
- Company type
- Private
- Founded year
- 2011
- Headcount range
- 1–10 employees
- Short description
- OncoTAb is a Charlotte, NC-based biotech founded in 2011 that develops a blood-based diagnostic test to aid breast cancer detection in women with dense breast tissue, a population where mammography sensitivity is reduced.
- Ownership category
- akta.pro rank
OncoTAb industry classification
Industry- Product category
- Breast Cancer Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)
- akta.pro secondary industries
- Breast Oncology (HLAKAFAJ), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Bioanalytical Testing (PK/ADA/NAb) (HLAGADAA)
Keywords
Where OncoTAb is headquartered
LocationHeadquarters
- HQ city
- Charlotte
- HQ country
- United States
- HQ region
- North America
Markets served
OncoTAb business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
OncoTAb product offering
Product offeringCore offering
OncoTAb develops and commercializes a blood-based diagnostic test that aids breast cancer detection, specifically targeted at women with dense breast tissue where standard mammography has reduced sensitivity. The company's core offering is a proprietary lab-based blood test positioned as an adjunctive screening tool for breast cancer.
Differentiator
Problem solved
Functional benefit
Products and services
- OncoTAb Breast Cancer Blood Test A proprietary blood-based diagnostic test that aids breast cancer detection in women with dense breast tissue, intended for use as an adjunctive screening tool by healthcare providers, breast imaging centers, and diagnostic laboratories.
Companies that use OncoTAb
Customer profileIdeal customer profiles1 record
OncoTAb technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
OncoTAb partnerships and signals
Strategic signalRecent moves3 records
Expansion highlights2 records
OncoTAb competitors and assessment
Company assessmentDirect peers
- Volpara Health: Volpara Health provides breast density assessment and risk evaluation software used alongside mammography. It is a direct peer in the dense-breast diagnostic niche, addressing the same unmet need that OncoTAb targets.
- Natera: Natera offers Signatera, a blood-based tumor-informed assay for MRD and recurrence monitoring in oncology. It overlaps with OncoTAb's blood-based oncology diagnostic positioning, particularly in the breast cancer use case.
- Exact Sciences: Exact Sciences commercializes Cologuard (colorectal screening) and the Oncotype DX franchise for breast cancer. It is a direct peer in blood-and-molecular-based cancer diagnostics and a likely competitive reference point for breast cancer detection.
- NeoGenomics: NeoGenomics is a specialty oncology testing laboratory offering a broad menu of cancer diagnostics. It is a direct peer as a commercial oncology diagnostic lab competing for the same clinician and patient channels.
- Guardant Health: Guardant Health offers blood-based liquid biopsy tests for oncology including therapy selection and recurrence monitoring. It is a direct peer in blood-based oncology diagnostics with far greater scale and clinical evidence.
- GRAIL: GRAIL develops multi-cancer early-detection blood tests (e.g., Galleri). It is the most prominent direct competitor to OncoTAb's concept of blood-based cancer detection, albeit at a much broader (multi-cancer) and later stage.
Emerging players
- Biodesix: Biodesix develops blood-based diagnostic tests for lung cancer and other oncology indications. It is an emerging player with a similar blood-based oncology diagnostic model that competes for similar clinical and investor mindshare.
- Thrive Earlier Detection (Exact Sciences): Thrive was acquired by Exact Sciences and developed CancerSEEK, a multi-cancer blood detection test. It is an emerging-adjacent peer in the same multi-cancer / single-cancer blood detection category as OncoTAb.
Broad incumbents
- Hologic: Hologic is an established incumbent in women's health and breast cancer diagnostics, including mammography systems and biopsy devices. It represents the standard-of-care incumbent against which a blood-based adjunct test would compete.
- iCAD: iCAD provides AI-driven breast cancer detection and risk assessment solutions for mammography. It overlaps with OncoTAb's dense-breast detection focus through adjacent AI/imaging-based breast cancer diagnostics.
Market position
Strengths3 records
Weaknesses3 records
Competitive moat2 records
Key risks4 records
Key highlights4 records
Customer concentration
OncoTAb social profiles
Digital presenceOncoTAb financial estimates
Financial estimateRevenue estimate
Valuation estimate
OncoTAb leadership team
Management profileNumber of profiles
Profiles2 records
OncoTAb funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
OncoTAb M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about OncoTAb
What does OncoTAb do?
OncoTAb develops and commercializes a blood-based diagnostic test that aids breast cancer detection, specifically targeted at women with dense breast tissue where standard mammography has reduced sensitivity. The company's core offering is a proprietary lab-based blood test positioned as an adjunctive screening tool for breast cancer.
When was OncoTAb founded?
OncoTAb was founded in 2011. It employs 1 to 10 people.
Where is OncoTAb based?
OncoTAb is headquartered in Charlotte, United States, in the North America region.
Who are OncoTAb's main competitors?
Direct peers on record are Volpara Health, Natera, Exact Sciences, NeoGenomics, Guardant Health and GRAIL. Emerging players are Biodesix and Thrive Earlier Detection (Exact Sciences). Broad incumbents are Hologic and iCAD.
Does OncoTAb have an API?
No public API is recorded for OncoTAb.
What industry is OncoTAb in?
OncoTAb's product category is Breast Cancer Diagnostics. Its primary akta.pro industry code is HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy), with a secondary code of HLAKAFAJ, Breast Oncology. Its NAICS code is 325413 and its SIC code is 2835.